The minor allele of GP6 T13254C is associated with decreased platelet activation and a reduced risk of recurrent cardiovascular events and mortality: Results from the SMILE-Platelets project

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 11, 2010, Pages 2377-2384

  Snoep, J D ^a   Gaussem, P ^b   Eikenboom, J C J ^a   Emmerich, J ^b   Zwaginga, J J ^a,c   Holmes, C E ^d   Vos, H L ^a   De Groot, P G ^e   Herrington, D M ^f   Bray, P F ^g   Rosendaal, F R ^a   van der Bom, J G ^a,c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INSERM   (France)

^c Leiden University Medical Centre ^*  (Netherlands)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Myocardial infarction; Platelet function; Prospective cohort study; Single nucleotide polymorphism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CLOPIDOGREL; CROSS LINKED COLLAGEN RELATED PEPTIDE; ESTROGEN; GESTAGEN; PADGEM PROTEIN; PEPTIDE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; BLOOD FLOWMETRY; CARDIOVASCULAR RISK; CONTROLLED STUDY; CYTOMETRY; ESTROGEN THERAPY; FOLLOW UP; GENETIC ASSOCIATION; HAZARD RATIO; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; UNSTABLE ANGINA PECTORIS;

AGED; ALLELES; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; PLATELET MEMBRANE GLYCOPROTEINS; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; PROTEIN ISOFORMS; RECURRENCE;

EID: 78149266916     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.04018.x     Document Type: Article

References (37)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
2. Breet NJ, Van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, Van Der Heyden JA, Rensing BJ, Suttorp MJ, Hackeng CM, Ten Berg JM. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010; 303: 754-62.
3. Snoep JD, Hovens MMC, Eikenboom JCJ, Van Der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593-9.
4. Snoep JD, Hovens MMC, Eikenboom JCJ, Van Der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007; 154: 221-31.
5. Snoep JD, Roest M, Barendrecht AD, De Groot PG, Rosendaal FR, Van Der Bom JG. High platelet reactivity is associated with myocardial infarction in premenopausal women: a population-based case-control study. J Thromb Haemost 2010; 8: 906-13.
6. Heemskerk JW, Siljander PR, Bevers EM, Farndale RW, Lindhout T. Receptors and signalling mechanisms in the procoagulant response of platelets. Platelets 2000; 11: 301-6.
7. Croft SA, Samani NJ, Teare MD, Hampton KK, Steeds RP, Channer KS, Daly ME. Novel platelet membrane glycoprotein VI dimorphism is a risk factor for myocardial infarction. Circulation 2001; 104: 1459-63.
8. Johnson AD, Yanek LR, Chen MH, Faraday N, Larson MG, Tofler G, Lin SJ, Kraja AT, Province MA, Yang Q, Becker DM, O'Donnell CJ, Becker LC. Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nat Genet 2010; 42: 608-13.
9. Watkins NA, O'Connor MN, Rankin A, Jennings N, Wilson E, Harmer IJ, Davies L, Smethurst PA, Dudbridge F, Farndale RW, Ouwehand WH. Definition of novel GP6 polymorphisms and major difference in haplotype frequencies between populations by a combination of in-depth exon resequencing and genotyping with tag single nucleotide polymorphisms. J Thromb Haemost 2006; 4: 1197-205.
10. Joutsi-Korhonen L, Smethurst PA, Rankin A, Gray E, Ijsseldijk M, Onley CM, Watkins NA, Williamson LM, Goodall AH, De Groot PG, Famdale RW, Ouwehand WH. The low-frequency allele of the platelet collagen signaling receptor glycoprotein VI is associated with reduced functional responses and expression. Blood 2003; 101: 4372-9.
11. Jones CI, Garner SF, Angenent W, Bernard A, Berzuini C, Burns P, Farndale RW, Hogwood J, Rankin A, Stephens JC, Tom BD, Walton J, Dudbridge F, Ouwehand WH, Goodall AH. Mapping the platelet profile for functional genomic studies and demonstration of the effect size of the GP6 locus. J Thromb Haemost 2007; 5: 1756-65.
12. Jones CI, Bray S, Garner SF, Stephens J, De Bono B, Angenent WGJ, Bentley D, Burns P, Coffey A, Deloukas P, Earthrowl M, Farndale RW, Hoylaerts MF, Koch K, Rankin A, Rice CM, Rogers J, Samani NJ, Steward M, Walker A, et al. A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways. Blood 2009; 114: 1405-16.
13. Trifiro E, Williams SA, Cheli Y, Furihata K, Pulcinelli FM, Nugent DJ, Kunicki TJ. The low frequency isoform of platelet GPVI (GPVIb) attenuates ligand-mediated signal transduction but not receptor expression or ligand binding. Blood 2009; 114: 1893-9.
14. Kunicki TJ, Williams SA, Nugent DJ, Harrison P, Segal HC, Syed A, Rothwell PM. Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease. Thromb Haemost 2009; 101: 123-33.
15. Lepantalo A, Mikkelsson J, Resendiz JC, Viiri L, Backman JT, Kankuri E, Karhunen PJ, Lassila R. Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost 2006; 95: 253-9.
16. Ollikainen E, Mikkelsson J, Perola M, Penttila A, Karhunen PJ. Platelet membrane collagen receptor glycoprotein VI polymorphism is associated with coronary thrombosis and fatal myocardial infarction in middle-aged men. Atherosclerosis 2004; 176: 95-9.
17. Takagi S, Iwai N, Baba S, Mannami T, Ono K, Tanaka C, Miyata T, Miyazaki S, Nonogi H, Goto Y. A GPVI polymorphism is a risk factor for myocardial infarction in Japanese. Atherosclerosis 2002; 165: 397-8.
18. Cole VJ, Staton JM, Eikelboom JW, Hankey GJ, Yi Q, Shen Y, Berndt MC, Baker RI. Collagen platelet receptor polymorphisms integrin alpha2beta1 C807T and GPVI Q317L and risk of ischemic stroke. J Thromb Haemost 2003; 1: 963-70.
19. Qin Q, Zhao BR, Mao YM, Cui RZ, Kou L, Li YL, Zhao FM, Hui RT. Association of matrix metalloproteinase-9 and platelet membrane glycoprotein VI polymorphisms with acute coronary syndrome. Zhonghua Xin Xue Guan Bing Za Zhi 2005; 33: 622-6.
20. Motovska Z, Kvasnicka J, Widimsky P, Petr R, Hajkova J, Bobcikova P, Osmancik P, Odvodyova D, Katina S. Platelet glycoprotein GP VI 13254C allele is an independent risk factor of premature myocardial infarction. Thromb Res 2010; 125: e61-4.
21. Boettiger C, Koch W, Mehilli J, Schoemig A, Kastrati A. Glycoprotein VI polymorphisms and outcome after percutaneous coronary interventions. Thromb Haemost 2007; 97: 673-4.
22. Bray PF, Howard TD, Vittinghoff E, Sane DC, Herrington DM. Effect of genetic variations in platelet glycoproteins Ibalpha and VI on the risk for coronary heart disease events in postmenopausal women taking hormone therapy. Blood 2007; 109: 1862-9.
23. Bezemer ID, Bare LA, Doggen CJ, Arellano AR, Tong C, Rowland CM, Catanese J, Young BA, Reitsma PH, Devlin JJ, Rosendaal FR. Gene variants associated with deep vein thrombosis. JAMA 2008; 299: 1306-14.
24. Tregouet DA, Heath S, Saut N, Biron-Andreani C, Schved JF, Pernod G, Galan P, Drouet L, Zelenika D, Juhan-Vague I, Alessi MC, Tiret L, Lathrop M, Emmerich J, Morange PE. Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. Blood 2009; 113: 5298-303.
25. Doggen CJM, Manger Cats V, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998; 97: 1037-41.
26. Van Der Krabben MD, Rosendaal FR, Van Der Bom JG, Doggen CJM. Polymorphisms in coagulation factors and the risk of recurrent cardiovascular events in men after a first myocardial infarction. J Thromb Haemost 2008; 6: 720-5.
27. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-13.
28. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 49-57.
29. Yee DL, Sun CW, Bergeron AL, Dong JF, Bray PF. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood 2005; 106: 2723-9.
30. Yee DL, Bergeron AL, Sun CW, Dong JF, Bray PF. Platelet hyperreactivity generalizes to multiple forms of stimulation. J Thromb Haemost 2006; 4: 2043-50.
31. Goodall AH, Appleby J. Flow-cytometric analysis of platelet-membrane glycoprotein expression and platelet activation. Methods Mol Biol 2004; 272: 225-53.
32. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, Dixon RJ, Meitinger T, Braund P, Wichmann HE, Barrett JH, Konig IR, Stevens SE, Szymczak S, Tregouet DA, Iles MM, Pahlke F, Pollard H, Lieb W, Cambien F, et al. Genomewide association analysis of coronary artery disease. N Engl J Med 2007; 357: 443-53.
33. Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol 2002; 3: 425-30.
34. Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost 2004; 30: 95-108.
35. Holmes CE, Levis JE, Ornstein DL. Activated platelets enhance ovarian cancer cell invasion in a cellular model of metastasis. Clin Exp Metastasis 2009; 26: 653-661.
36. Jain S, Russell S, Ware J. Platelet glycoprotein VI facilitates experimental lung metastasis in syngenic mouse models. J Thromb Haemost 2009; 7: 1713-17.
37. Van Der Bom JG, Heckbert SR, Lumley T, Holmes CE, Cushman M, Folsom AR, Rosendaal FR, Psaty BM. Platelet count and the risk for thrombosis and death in the elderly. J Thromb Haemost 2009; 7: 399-405.